InnoCare is a biopharmaceutical company specializing in drug development for the treatment of cancer and autoimmune diseases. It produces Orelabrutinib, a selective and irreversible small-molecule BTK inhibitor for patients with B-cell malignancies. In addition, the company aims to develop drugs for treating autoimmune diseases induced by T-cell dysfunction.